Sypharma has a proven track record of successful drug development within the national and international arena and welcomes collaboration on new pharmaceutical innovations.
Companies seeking to develop new pharmaceuticals or medicial devices should be mindful of ensuring reproducibility in their product and their results as early as possible. We recommend that development is discussed early in a product lifecycle so that a drug master file is begun and ensures quick progress to product for clinical trials.
GMP status of a drug master file is of critical importance to companies seeking to licence out their technologies and early consideration of this crucial component means that there is no need to duplicate costly early stage work in the scale-up process.
Sypharma has the technology and the expertise to be your single point of contact during the drug development process and enables you to keep all your development within world-class Australian facilities from pre-clinical to phase III and beyond.